II. Indications
III. Labs: HIV Diagnosis (2014 U.S. protocol)
- Step 1: HIV-1/HIV-2 EIA Antibody Test with p24 Antigen testing (fourth generation)- Negative- No HIV-1 or HIV-2 Antibody or p24 Antigen
- p24 Antigen is detectable by HIV Testing as early as 2 weeks after infection
- High Negative Predictive Value
- Retest in 2-4 weeks if new HIV Exposure in prior 2 weeks
 
- Positive- Go to Step 2 for discriminatory assay
 
 
- Negative
- Step 2: HIV-1/HIV2 Discriminatory Assay (Multispot)- Negative for HIV-1 and HIV-2
- HIV-1 Antibody positive (most common in U.S.)- Obtain viral load
- Start Combination Antiretroviral Therapy
 
- HIV-2 Antibody positive (West Africa, nRTI resistance)
 
- Step 3: HIV-1 RNA Nucleic Acid Amplification Test (NAT or NAAT) for HIV RNA Viral Activity- Negative NAAT- Retest in 2-4 if new HIV Exposure in prior 2 week
 
- Positive NAAT- Acute HIV Infection (although rare False Positive tests occur)
- Start Combination Antiretroviral Therapy
 
 
- Negative NAAT
IV. Labs: Timing of HIV Test detection (from transmission)
- Days 10-12 (1-2 weeks)- HIV 1 Nucleic Acid amplification test (NAAT) for HIV RNA Viral Activity positive
 
- Days 15-17 (2 weeks)- HIV p24 Antigen positive
 
- Day 21 (3 weeks)- HIV-1/HIV-2 EIA Test (fourth generation) positive
 
- Day 28 (4 weeks)- HIV-1/HIV2 Discriminatory Assay (Multispot)
 
- Day >35 (5 weeks)- Unigold OraQuick positive
- HIV Western Blot positive
 
- References
V. Labs: HIV Screening
- First line screening (recommended)
- Other HIV rapid Screening Tests (office based, perform Multispot/NAAT testing if positive)- Uni-Gold Recombigen
- Alere Determine
- OraQuick  (oral swab based)- Available as In-Home HIV Test as of 2013
- Approved for age 17 years old and older
- Results in 20-40 minutes
- Test Sensitivity- Approaches 99% when performed in clinic
- Drops to 92% (False Negative Rate: 1 in 12) when performed at home (due to user error)
 
- Test Specificity: 99.98% (False Positive Rate: 1 in 5000)
- Most accurate at 3 months after exposure
 
 
VI. Labs: HIV Tests (confirmatory, discriminatory and activity tests)
- 
                          CD4 Cell Count
                          - Best marker of HIV-related Immunosuppression, infection duration and prognosis
- Varies from person to person, lab to lab, by time of day, and most significantly by acute comorbid illness
 
- HIV Enzyme Linked Immosorbent Assay (EIA, ELISA) Antibody Test- Combined with p24 for increased Test Sensitivity
- Positive at 3-8 weeks after exposure
- Initial False Negative tests in first 2 weeks
- Test Sensitivity: 99.5%
- False Positive risk and requires confirmatory testing (e.g. HIV )
 
- HIV-1/HIV2 Discriminatory Assay (Multispot)- Detects circulating antibodies to both HIV-1 and HIV-2
- Discriminates between HIV-1 and HIV-2
 
- 
                          HIV-1 RNA Nucleic Acid Amplification Test (NAT or NAAT) for HIV RNA Viral Activity (HIV Viral Load)- Test Sensitivity: 100% sensitive
- Test Specificity: 97.4% Specific
- Positive at 11-12 days from infection
- Higher rate of False Positives
- Low counts (<10,000) are often False Positives
 
- p24 Antigen (direct detection)- Positive at 14-15 days from infection (falls within 6-8 weeks)
- Used as part of screening protocol (see above)
- Consider for Acute Retroviral Syndrome diagnosis
- Test Sensitivity: 88.7% (high False Negative Rate)
- Test Specificity: 100%
- (2001) Ann Intern Med 134:25-29 [PubMed]
 
- 
                          HIV Western Blot Assay- Detects HIV Antigens (p24, gp41, gp120, gag, pol, env Proteins)
- Used as a second-line confirmatory test for first generation HIV Tests
- Used as a third-line confirmatory tests for 4th generation combination HIV-1/HIV-2/p24 tests- Obtained if second-line Multispot or NAAT testing is negative, but initial testing positive
 
 
VII. Efficacy: False-negative HIV Test causes (Consider repeat testing or HIV Viral Load testing)
- Acute seroconversion (<4 weeks of HIV Infection)
- Advanced AIDS (Antibody based tests)
- Autoimmune Condition
- Hemodialysis patients (Renal Failure)
- Multiple pregnancies
- Multiple transfusions
- Cystic Fibrosis
- Liver disease
- Intravenous Drug Abuse
- 
                          Immunization
                          - HIV Vaccination (experimental only)
- Recent other Immunization
 
VIII. Labs: Related Sexually Transmitted Disease Testing
IX. Labs: Disease Screening Related to Advanced HIV or AIDS
- 
                          Tuberculin Skin Test (PPD, Mantoux)- Consider Quantiferon-TB instead
- Dose: 0.5 cc injected (contrast with standard 0.1 cc)
- Positive: >5 mm (contrast with standard 10 mm)
 
- Cytomegalovirus Serology (CMV)
- Toxoplasmosis Titer
- Gynecologic examination with Pap Smear- HIV associated with advanced Cervical Cancer
 
